《新股消息》邁越科技(02501.HK)明起招股 每手入場費2,828.2元
內地IT解決方案服務商邁越科技(02501.HK)公布招股詳情,擬全球發售1.25億股,香港公開發售佔一成,國際發售佔九成,每股招股價介乎1.05元至1.4元,每手2,000股計,一手入場費2,828.2元。
該股明日(28日)起招股,10月4日中午12時截止,預期10月11日掛牌,獨家保薦人為華富建業企業融資。
如以招股價中位數1.225元計,料集資約1.53億元,所得款項擬用於支持現有及擴張潛在項目、設立深圳研發中心、市場推廣與完善團隊、提升信息基礎建設、優化資本結構及一般營運用途。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.